Company intelligence / Profile preview

MolMed

Ownership: Private
Employees: ~200
Development stage: Phase 3

Overview

MolMed was a clinical-stage biotechnology company specializing in the research, development, manufacturing, and clinical validation of innovative cell and gene therapies for cancer. The company developed both drugs targeting acute tumor mass as well as highly selective therapies for residual disease. It filed at least 20 patents related to biotechnology, gene expression, molecular biology, and chimeric antigen receptors.

Therapeutic areas: Oncology
Modalities: Cell therapiesGene therapiesChimeric Antigen Receptors (CARs)
Industry: Biotech

Drug pipeline

3 assets

Zalmoxis

Phase 3

Indications: High-risk acute leukemia

2 more assets in the full pipeline.

Partnerships

Autolus Therapeutics plc – multi-year agreement for manufacturing support signed in March 2020

Beyond the preview

Go deeper on MolMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MolMed.